NAFLD (Non-Alcoholic Fatty Liver Disease) Activity Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- No activity0–0
- Mild activity1–2
- Moderate activity3–5
- Marked activity6–8
The NAFLD (Non-Alcoholic Fatty Liver Disease) Activity Score calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include steatosis. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses steatohepatitis based on histological findings in NAFLD patients. The NAS evaluates disease activity by scoring three histological features: steatosis, lobular inflammation, and hepatocellular ballooning.
Clinical Indication
The NAFLD (Non-Alcoholic Fatty Liver Disease) Activity Score is indicated for bedside clinical practice to support Diagnoses steatohepatitis based on histological findings in NAFLD patients. The NAS evaluates disease activity by scoring three histological features: steatosis, lobular inflammation, and hepatocellular ballooning.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy. Guideline pearl: NAS ≥4 is recommended for admission into interventional trials for NASH.
NAS = Steatosis score (0-3) + Lobular inflammation score (0-3) + Hepatocellular ballooning score (0-2)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| steatosis | string | Yes | Percentage of hepatocytes containing fat droplets on liver biopsy |
| lobular_inflammation | string | Yes | Number of inflammatory foci per 200× microscopic field |
| ballooning | string | Yes | Hepatocellular ballooning (enlarged hepatocytes with rarefied cytoplasm) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | No activity | No NAFLD activity |
| 1–2 | Mild activity | Mild NAFLD activity |
| 3–5 | Moderate activity | Moderate NAFLD activity |
| 6–8 | Marked activity | Marked NAFLD activity |
Evidence-Based References (EBM)
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21. doi: 10.1002/hep.20701.DOI: 10.1002/hep.20701
- Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011 Mar;53(3):810-20. doi: 10.1002/hep.24127.DOI: 10.1002/hep.24127